Randomized intergroup comparison of bacillus calmette-guerin immunotherapy and mitomycin C chemotherapy prophylaxis in superficial transitional cell carcinoma of the bladder a southwest oncology group study-Reference-Cited by-同舟云学术

Randomized intergroup comparison of bacillus calmette-guerin immunotherapy and mitomycin C chemotherapy prophylaxis in superficial transitional cell carcinoma of the bladder a southwest oncology group study

Published:1995-05 Issue:3 Volume:1 Page:119-126
ISSN:1078-1439
Container-title:Urologic Oncology: Seminars and Original Investigations
language:en
Short-container-title:Urologic Oncology: Seminars and Original Investigations

Author:

Lamm Donald L.,Blumenstein Brent A.,David Crawford E.,Crissman John D.,Lowe Bruce A.,Smith Joseph A.,Sarosdy Michael F.,Schellhammer Paul F.,Sagalowsky Arthur I.,Messing Edward M.,Loehrer Pat,Barton Grossman H.

Publisher

Elsevier BV

Subject

Urology,Oncology

Reference25 articles.

1. Carcinoma in situ;Lamm;Urol Clin N Amer,1992

2. Experience with bacillus Calmette-Guerin in patients with superficial bladder carcinoma;Brosman;J Urol,1982

3. Intravesical therapy comparing BCG, Adriamycin, and Thiotepa in 200 patients with superficial bladder cancer: a randomized prospective study;Martinez-Pineiro;Progress in Clinical and Biological Research,1989

4. A Randomized Trial of Intravesical Doxorubicin and Immunotherapy with Bacillus Calmette-Guerin for Transitional Cell Carcinoma of the Bladder;Lamm;N Engl J Med,1991

5. Immunotherapy versus chemotherapy in the treatment of superficial bladder tumors;Lamm,1991

Cited by 128 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. BCG and bladder cancer. Forty-eight years after Morales report;Urologia Journal;2024-05-17

2. The Evolving Role of PD-(L)1 Inhibition in Optimizing Outcomes for High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC): A Podcast;Advances in Therapy;2024-02-02

3. Seminal papers in urology: maintenance Bacillus Calmette-Guerin (BCG) immunotherapy for recurrent Ta, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized southwest oncology group study (SWOG-8507);BMC Urology;2023-11-24

4. Diminished Short-Term Efficacy of Reduced-Dose Induction BCG in the Treatment of Non-Muscle Invasive Bladder Cancer;Cancers;2023-07-24

5. The efficacy and safety outcomes of lower dose BCG compared to intravesical chemotherapy in non–muscle-invasive bladder cancer: A network meta-analysis;Urologic Oncology: Seminars and Original Investigations;2023-06